Massive Bio, Azra AI forge collaboration to boost cancer patient enrollment

Cancer patient matchmaker Massive Bio and healthcare tech Azra AI are partnering to improve cancer clinical care through early identification and targeted treatment options for patients.

Azra's tech interprets pathology reports in fractions of a second compared to the current two to three minutes allowing clinicians to identify about 10% of positive results quickly. The time reduction can be pivotal in getting patients treatments sooner for a better chance of survival, the company said in a Nov. 10 press release. More than 200 hospitals, including HCA Healthcare, are using the program today.

Massive Bio’s platform uses artificial intelligence to help patients find clinical trials relevant to their specific cancer much faster while also helping fill an industry need to identify and include a more diverse population.

In September, Massive Bio announced an expansion of its footprint in Europe with the aid of a $9 million investment and three new key hires.

The company plans to enroll 100,000 cancer patients by expanding to 19 countries as part of its 100K Cancer Clinical Trial Singularity Program. As of September, Massive Bio had signed up more than 66,000 patients.